

1 **A gain-of-function variant in *NNT* causes premature diffuse familial**  
2 **sebaceous hyperplasia**

3 **Running head:** *NNT* variant causes PDFSH

4  
5 Lina Liang,<sup>1\*</sup> Sheng Wang,<sup>2\*</sup> Shimiao Huang,<sup>1</sup> Yonghu Sun,<sup>3</sup> Sha Peng,<sup>1</sup> Christos C.  
6 Zouboulis,<sup>4</sup> Amir M. Hossini,<sup>4</sup> Quan Chen,<sup>5†</sup> Huijun Wang,<sup>1†</sup> Zhimiao Lin<sup>1†</sup>

7  
8 <sup>1</sup>Dermatology Hospital, Southern Medical University, Guangzhou, China

9 <sup>2</sup>Department of Dermatology, West China Hospital, Sichuan University, Chengdu, China

10 <sup>3</sup>Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of  
11 Medical Sciences, Jinan, Shandong, China

12 <sup>4</sup>Departments of Dermatology, Venereology, Allergology and Immunology, Staedtisches  
13 Klinikum Dessau, Brandenburg Medical School Theodor Fontane and Faculty of Health  
14 Sciences Brandenburg, Dessau, Germany

15 <sup>5</sup>Department of General Dermatology, Guangzhou Dermatology Hospital, Guangzhou,  
16 China

17 \*contributed equally to this work and are joint first authors.

18 †contributed equally to this work and are joint senior authors.

19  
20 **Corresponding author:** Zhimiao Lin

21 **Email:** [zhimiaolin@bjmu.edu.cn](mailto:zhimiaolin@bjmu.edu.cn)

22  
23 **Acknowledgments:** We thank the patients for participating in this study. We also thank  
24 Professor Yi Han (Sun Yat-sen University Cancer Center, Guangzhou, China) for  
25 valuable technical assistance.

1 **Funding sources:** This work was supported by the National Natural Science Foundation  
2 of China (grant numbers 82373459 to Z.L. and 82373500 to H.W.).

3 **Conflicts of interest:** The authors declare no conflicts of interest except for Christos C.  
4 Zouboulis. Christos C. Zouboulis has received honoraria as a consultant for Almirall,  
5 Biogen, Boehringer Ingelheim, CLS Behring, Eli Lilly and Company, Estée Lauder,  
6 Idorsia, Incyte, L'Oréal, MSD, NAOS-BIODERMA, Novartis, PPM, Sanofi, ShiRhom,  
7 Takeda, UCB, and ZuraBio and lecture honoraria from Almirall, Amgen, NAOS-  
8 BIODERMA, Biogen, BMS, L'Oréal, Novartis, Pfizer, and UCB. His departments have  
9 received grants from his participation as a clinical and research investigator for  
10 AstraZeneca, Boehringer Ingelheim, BMS, Brandenburg Medical School Theodor  
11 Fontane, EADV, European Union, German Federal Ministry of Education and Research,  
12 GSK, Incyte, InflaRx, MSD, Novartis, Relaxera, Sanofi, and UCB. He is President of the  
13 EHSF e.V., President of the Deutsches Register Morbus Adamantiades-Behçet e.V.,  
14 Board member of the International Society for Behçet's Disease, coordinator of the  
15 ALLOCATE Skin group of the ERN Skin, and chair of the ARHS Task Force group of  
16 the EADV. He is Editor of the EADV News, and co-copyright holder of IHS4 on behalf  
17 of the EHSF e.V.

18 **Data availability:** The data for this study are available from the authors on reasonable  
19 request.

20 **Ethics statement:** This study was approved by the Clinical Research Ethics Committee  
21 of Dermatology Hospital, Southern Medical University, and was conducted in conformity  
22 with the principles of the Declaration of Helsinki.

23 **Patient consent:** Written patient consent for publication was obtained.

24  
25  
26

1

2 **What is already known about this topic?**

- 3 • Premature diffuse familial sebaceous hyperplasia (PDFSH) is characterized by  
4 the gradual appearance of small, round yellow or flesh-colored papules on the  
5 face, often accompanied by hyperseborrhea, typically emerging at or after  
6 puberty with a positive family history.
- 7 • Nicotinamide nucleotide transhydrogenase (NNT), an inner mitochondrial  
8 membrane-bound enzyme, mediates proton gradient-dependent transfer of  
9 hydride ion from NADH to NADP<sup>+</sup>, thereby serving as a principal source of  
10 NADPH production. This reduced coenzyme critically sustains cellular redox  
11 homeostasis through its antioxidant capacity.
- 12 • Enhanced NNT activity has been reported to protect gastric cancer cells from  
13 ferroptosis.

14

15 **What does this study add?**

- 16 • A missense variant c.2063T>G (p.Leu688Trp) in the *NNT* gene was identified in  
17 three unrelated families with PDFSH.
- 18 • The *NNT* c.2063T>G variant resulted in elevated NADPH/NADP<sup>+</sup> ratio and GSH  
19 levels and consequent reduction of ROS in patient's primary keratinocytes and  
20 sebaceous gland cells SZ95, leading to enhanced cellular antioxidant capacity.
- 21 • Evidences suggesting reduced ferroptosis susceptibility in patients' sebaceous  
22 gland were demonstrated. SZ95 sebocytes expressing NNT-Leu688Trp confers  
23 resistance to ferroptosis, which might result in the hyperplasia of sebaceous gland  
24 in the patients with PDFSH.

25

26

1 **What is the translational message?**

- 2 • We first link a gain-of-function variant in *NNT* to autosomal dominant PDFSH.  
3 • Our study implicates the essential role of NNT in regulating antioxidant capacity  
4 and cell survival of sebocytes.  
5  
6

7 **Abstract**

8 **Backgrounds** Premature diffuse familial sebaceous hyperplasia (PDFSH) constitutes a  
9 distinct clinical variant of sebaceous hyperplasia, characterized by three hallmark  
10 features: early disease onset, characteristic sparing of perioral and periocular regions, and  
11 a positive family history. To date, the pathogenic gene underlying PDFSH remains  
12 unidentified.

13 **Objectives** The aim of this study was to identify the underlying gene and the  
14 pathogenesis of three familial cases with autosomal dominant PDFSH.

15 **Methods** Whole-exome sequencing was performed in two unrelated families of  
16 autosomal dominant PDFSH. The identified candidate gene was further screened for  
17 variants in an additional case using Sanger sequencing. The ultrastructure of sebaceous  
18 glands was analyzed by transmission electron microscopy (TEM). Immunofluorescence  
19 staining was performed to assess lipid peroxidation levels in sebaceous glands.  
20 Functional analyses included quantification of NADPH/NADP<sup>+</sup> ratio, glutathione (GSH)  
21 levels, and reactive oxygen species (ROS) levels. Flow cytometry with C11-BODIPY and

1 propidium iodide (PI) staining was performed to assess lipid peroxidation and cell  
2 viability, respectively.

3 **Results** We identified a missense variant c.2063T>G (p.Leu688Trp) in *NNT* in all  
4 affected members across the three PDFSH families. Both patient-derived keratinocytes  
5 and NNT-knockdown SZ95 sebocytes overexpressing the mutant nicotinamide nucleotide  
6 transhydrogenase (NNT) exhibited enhanced antioxidant capacity, evidenced by elevated  
7 NADPH/NADP<sup>+</sup> ratio, increased GSH levels, and reduced ROS production compared to  
8 controls. Ultrastructural analysis revealed a decreased proportion of mitochondria with  
9 cristae disorganization, and immunofluorescence staining showed reduced levels of lipid  
10 peroxidation in the patient's sebaceous glands, suggesting decreased ferroptosis  
11 susceptibility. *In vitro* experiments confirmed that the *NNT* c.2063T>G variant protects  
12 SZ95 sebocytes from ferroptosis through oxidative stress mitigation.

13 **Conclusions** We identified a gain-of-function variant c.2063T>G (p.Leu688Trp)  
14 in *NNT* underlying PDFSH. This genetic variant enhances antioxidant capacity of NNT  
15 while attenuating intracellularly accumulated ROS levels, and reduces sebaceous glands'  
16 susceptibility to ferroptosis.

17

18

19

20

## 1 **Introduction**

2 Sebaceous gland hyperplasia (SGH), a common benign dermatological entity, is clinically  
3 manifested as solitary or clustered yellowish papules. These lesions predominantly arise  
4 in sebaceous gland-rich areas of the face, particularly the malar eminences and frontal  
5 region. Epidemiologically, SGH demonstrates a predilection for individuals beyond the  
6 fifth decade of life.<sup>1</sup> Early-onset manifestations may also occur in several clinical  
7 contexts including long-term cyclosporine administration,<sup>2,3</sup> Muir-Torre syndrome,<sup>4</sup>  
8 familial cases,<sup>5,6</sup> and X-chromosomal hypohidrotic ectodermal dysplasia.<sup>7</sup>

9  
10 Premature (or presenile) diffuse familial sebaceous hyperplasia (PDFSH, MIM  
11 601700) is a rare clinical variant of SGH, distinguished by three hallmark features: (1)  
12 early onset typically during or soon after puberty, (2) distinctive sparing of the perioral  
13 and periocular regions, and (3) evidence of familial clustering.<sup>5,6</sup> While the precise  
14 molecular etiology and pathogenic mechanisms of PDFSH are not yet fully characterized,  
15 the features of early disease onset and multigenerational disease aggregation strongly  
16 suggest constitutional genomic alterations as the underlying cause.

17  
18 Nicotinamide nucleotide transhydrogenase (NNT), an integral inner mitochondrial  
19 membrane protein encoded by the *NNT* gene, serves as a critical antioxidant enzyme by

1 leveraging a proton gradient to drive NADPH synthesis.<sup>8,9</sup> This reaction involves hydride  
2 transfer from NADH to NADP<sup>+</sup>, generating up to 50% of the mitochondrial NADPH pool  
3 essential for redox homeostasis.<sup>8-10</sup> In the cellular defense system against oxidative stress,  
4 NNT maintains redox balance by generating NADPH to sustain a high ratio of the  
5 reduced glutathione/glutathione disulfide (GSH/GSSG), thereby protecting mitochondria  
6 from superoxide anion, hydrogen peroxide, and related reactive oxygen species (ROS) to  
7 prevent oxidative damage-induced cell death.<sup>8,11,12</sup> In 2012, Meimaridou *et al.* first  
8 reported that *NNT* is the pathogenic gene for familial glucocorticoid deficiency (FGD,  
9 MIM 614736).<sup>13</sup> Biallelic loss-of-function variants in *NNT* impair oxidative stress  
10 responses, trigger adrenal cell apoptosis, and disrupt steroidogenesis, resulting in  
11 FGD.<sup>13,14</sup> In addition, NNT exhibits protumorigenic activity by orchestrating redox  
12 homeostasis in multiple solid malignancies, particularly in clinically aggressive subtypes  
13 such as non-small cell lung cancer and gastric carcinoma.<sup>10,15</sup>

14  
15 Ferroptosis is an iron-dependent, non-apoptotic programmed cell death characterized  
16 by excessive lipid peroxidation and disrupted redox homeostasis.<sup>16</sup> The process is  
17 triggered by ROS-mediated peroxidation cascades, resulting in toxic lipid peroxide  
18 accumulation and eventual plasma membrane disintegration.<sup>16</sup> Ultrastructurally,  
19 ferroptotic cells usually exhibit characteristic mitochondrial changes including shrinkage,  
20 cristae disorganization, and outer membrane rupture.<sup>11,17</sup> Emerging evidence has

1 implicated the crucial roles of ferroptosis in sebaceous gland biology, with recent studies  
2 showing that photothermal therapy for acne vulgaris reduces sebum secretion through  
3 induction of sebocyte ferroptosis.<sup>18</sup>

4  
5 Here, we identify a missense variant c.2063T>G (p.Leu688Trp, rs1313691502) in  
6 the *NNT* gene as the genetic basis for autosomal dominant PDFSH in three unrelated  
7 families. We demonstrated that the *NNT* variant exerts a gain-of-function property,  
8 conferring ferroptosis resistance in sebocytes through ROS suppression. This mechanism  
9 may underlie the development of NNT-associated sebaceous hyperplasia.

## 11 **Patients and methods**

### 12 **Participants**

13 Three unrelated families (Fam1-Fam3) were included in the study. Written informed  
14 consent was obtained from all participants. This study was approved by the Clinical  
15 Research Ethics Committee of the Dermatology Hospital, Southern Medical University.

### 17 **Cell culture**

18 Lesional skin specimens were obtained followed by subcutaneous fat excision. Tissues  
19 were disinfected sequentially with povidone-iodine and 75% ethanol, then mechanically



1 minced into < 2mm fragments. Epidermal-dermal separation was achieved by incubating  
2 the tissue in 2.5 mg/mL dispase II at 4°C for 14-16 hours. Isolated epidermis was  
3 enzymatically dissociated using 0.25% trypsin at 37°C for 5-10 min, followed by  
4 neutralization and gentle trituration. Cell suspensions were centrifuged, resuspended in  
5 keratinocyte growth medium, and plated on cell culture dish containing coating  
6 maintained at 37°C with 5% CO<sub>2</sub>.

7  
8 The immortalized human sebaceous gland cell line SZ95<sup>19</sup> was cultured in Sebomed®  
9 basal medium (Sigma-Aldrich, F8205) supplemented with 5 ng/mL human epidermal  
10 growth factor (PeproTech, AF-100-15) and 10% fetal bovine serum (Gibco) at 37°C with  
11 5% CO<sub>2</sub>.

### 12 13 **Generation of NNT-overexpressing SZ95 cell Lines**

14 Firstly, NNT-knockdown SZ95 sebocytes were generated by lentiviral transduction using  
15 *NNT*-specific shRNA (GeneCopoeia, LPP-HSH097229-LVRU6H), followed by  
16 hygromycin B selection. For exogenous NNT expression, CMV promoter-driven  
17 lentiviral vectors expressing short hairpin RNA (shRNA)-resistant (r) human *NNT* cDNA  
18 (NM\_012343.3) with C-terminal 3×Flag tags was generously provided by Dr Han.<sup>20</sup> The  
19 NNT-Leu688Trp variant (rNNT-Leu688Trp) was obtained by site-directed mutagenesis.  
20 The recombinant lentiviral plasmids were co-transfected with packaging plasmids

1 (psPAX2 and pMD2.G) into HEK293T cells to generate replication-incompetent  
2 lentiviral particles. Stable NNT-overexpressing cell lines were generated by transducing  
3 NNT-knockdown SZ95 sebocytes with lentiviral particles, followed by puromycin  
4 selection. Control cell lines were established using empty vector (EV) lentivirus under  
5 identical conditions.

6

### 7 **NADPH/NADP<sup>+</sup>, GSH and ROS detection assay**

8 Intracellular NADPH/NADP<sup>+</sup> and GSH levels in the primary keratinocytes or SZ95  
9 sebocytes were quantified using the NADP/NADPH-Glo Bioluminescent Assay kit  
10 (Promega, G9082) and GSH-Glo Glutathione Assay kit (Promega, V6911) following the  
11 manufacturer's protocol.

12

13 Intracellular ROS levels were quantified using the peroxide-sensitive fluorescent  
14 probe 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA). Briefly, primary  
15 keratinocytes or SZ95 sebocytes were seeded in 6-well plates at a density of 200,000  
16 cells per well. After reaching confluence, the cells were washed twice with PBS,  
17 trypsinized, and washed once more with PBS. The cells were then incubated with 10  $\mu$ M  
18 DCFH-DA at 37°C for 30 min. Following three washes with PBS, cells were resuspended  
19 in 500  $\mu$ L PBS and analyzed for fluorescence intensity on BD Celesta flow cytometer  
20 with an excitation wavelength of 488nm. Data were analyzed using FlowJo v10 software.

1

## 2 **Results**

### 3 **Clinical and histopathologic manifestations of the patients**

4 Three unrelated Chinese families with autosomal dominant PDFSH were enrolled in this  
5 study (Figure 1d). All affected individuals developed multiple yellowish papules on the  
6 face at or after puberty (onset age ranging from 16 to 35 years), with a progressive  
7 increase in lesion number. Physical examination revealed multiple coalesced 1-5 mm  
8 yellowish to flesh-colored papules and plaques predominantly localized to the forehead  
9 and cheeks, with additional scattered lesions observed behind the ears, on the neck, and  
10 on the upper chest, sparing the perioral and periorbital regions (Figures 1a, b and S1a-d).  
11 Most patients reported facial greasiness. Histopathological analysis of the skin lesions  
12 from the probands of three families (Fam1:III-2, Fam2:II-2 and Fam3:II-1) demonstrated  
13 abnormal hypertrophic sebaceous glands in the upper dermis composed of abundant  
14 mature sebocytes and infiltration of sparse inflammatory cells in the superficial dermis  
15 (Figure 1c).

16

### 17 **Ultrastructural features of the skin lesion**

18 Ultrastructural examination of sebaceous glands from patient Fam2:II-2 and a healthy  
19 control was performed using transmission electron microscopy (TEM). Terminally

1 differentiated sebocytes from healthy control displayed mitochondria structural changes  
2 with cristae disorganization and loss of outer membrane integrity (Figure 2a),  
3 recapitulating the characteristic mitochondrial dysfunction patterns observed in  
4 ferroptotic cells.<sup>11,17</sup> In contrast, terminally differentiated sebocytes from Fam2:II-2  
5 displayed a significantly lower proportion of mitochondria with cristae disorganization  
6 compared to the control (Figure 2a, b). The morphological preservation suggests  
7 enhanced resistance to ferroptotic stress in the patient cells.

#### 9 **Identification of the *NNT* variant in patients**

10 For WES data, we focused on rare (MAF < 0.001), heterozygous non-synonymous  
11 variants in the same candidate gene present in all the four affected individuals (Fam1:II-  
12 2, Fam1:III-2, Fam1:III-3 and Fam2:II-2). A variant c.2063T>G (p.Leu688Trp,  
13 NM\_012343.3) in the *NNT* gene was identified in all the four affected individuals, which  
14 was validated by Sanger sequencing (Figure 2c). We further performed Sanger  
15 sequencing on the family members of Fam1, Fam2 and Fam3. Interestingly, we found  
16 that Fam3:II-1 and Fam3:II-2 harbored the same variant c.2063T>G in *NNT*. The *NNT*  
17 c.2063T>G variant was confirmed to co-segregate with the phenotype in all enrolled  
18 family members (Figure 1d) except Fam1:IV-1 who harbored the *NNT* variant but had not  
19 SGH. Given Fam1:IV-1 was only 16 years old and the onset of the disorder in other  
20 family members was around 20 years old, we assumed that Fam1:IV-1 might develop the

1 phenotype in a few years. Notably, the residue Leu688, which is located in the membrane  
2 domain (dII) of NNT, is highly conserved across species (Figure 2d) and was predicted to  
3 be “disease causing” *in silico* (<https://www.mutationtaster.org>). This variant is present in  
4 gnomAD in an extremely low frequency of 0.000003100 (5 in 1612868) but absent in  
5 East Asian.

### 7 **The c.2063T>G variant enhanced the antioxidant capacity of NNT**

8 NNT maintains mitochondria redox homeostasis by regenerating NADPH, which is  
9 essential for glutathione peroxidase-mediated GSSG reduction to GSH, thereby enabling  
10 efficient ROS detoxification.<sup>12</sup> To initially assess the functional impact of the  
11 *NNT* c.2063T>G variant, we assessed the NADPH/NADP<sup>+</sup> ratio, GSH levels, and ROS  
12 levels in primary keratinocytes derived from Fam2:II-2 and a healthy control. The results  
13 showed that NADPH/NADP<sup>+</sup> ratio and GSH levels were significantly upregulated in the  
14 primary keratinocytes from Fam2:II-2 compared to those of the control (Figure 3a, b).  
15 Consistently, the ROS levels were significantly reduced in the keratinocytes from  
16 Fam2:II-2 (Figure 3c).

17  
18 To further clarify the role of the *NNT* c.2063T>G variant in sebocytes, we  
19 overexpressed rNNT-WT and rNNT-Leu688Trp in NNT-knockdown SZ95 sebocytes  
20 (Figure S3e) and assessed NADPH/NADP<sup>+</sup> ratio, GSH levels, and ROS levels in each

1 group. To minimize interference from endogenous NNT in SZ95 sebocytes, which exhibit  
2 high baseline NNT expression, we established stable NNT-knockdown SZ95 sebocytes.  
3 Western blot analysis confirmed > 90% reduction in endogenous NNT protein levels  
4 compared to scramble shRNA control (Figure S3d). The cells overexpressing rNNT-  
5 Leu688Trp exhibited significantly elevated NADPH/NADP<sup>+</sup> ratio and GSH levels  
6 compared to the cells overexpressing rNNT-WT (Figure 3d, e), accompanied by a marked  
7 reduction in ROS levels (Figure 3f), indicating that the *NNT* c.2063T>G variant enhances  
8 the intracellular antioxidant capacity of NNT. Furthermore, consistent with *in vivo* data,  
9 we also observed different ultrastructural mitochondrial changes between SZ95 sebocytes  
10 transfected with rNNT-WT and rNNT-Leu688Trp treated with RSL3, a specific  
11 ferroptosis inducer. After treatment, cells expressing rNNT-WT exhibited extensive  
12 mitochondria with cristae disorganization (Figure S2a)—ultrastructural features  
13 characteristic of ferroptosis and mirroring the mitochondrial alterations seen in terminally  
14 differentiated sebocytes *in vivo*. In contrast, SZ95 sebocytes expressing rNNT-Leu688Trp  
15 showed a marked reduction in the proportion of such mitochondria (Figure S2a, b),  
16 further suggesting that the *NNT* c.2063T>G variant enhances ferroptosis resistance in  
17 sebocytes.

18

19 To exclude the possibility that functional changes are due to altered protein abundance  
20 of NNT, we performed qPCR and Western blot using primary keratinocytes from patient

1 Fam2:II-2 and a healthy control. As shown in Figures S3a and S3b, qPCR and Western  
2 blot analysis revealed no significant differences between the patient and healthy control,  
3 suggesting that the variant did not affect the transcription and translation of *NNT*.  
4 Similarly, Western blot was performed in *NNT*-knockdown SZ95 sebocytes  
5 overexpressing rNNT-Leu688Trp and those overexpressing rNNT-WT, which revealed  
6 comparable protein abundance of *NNT* (Figure S3d, e).

### 8 **Lipid peroxidation reduced in PDFSH patients**

9 Ferroptosis is an iron-dependent cell death pathway characterized by ROS accumulation  
10 leading to excessive lipid peroxidation and cell death.<sup>11</sup> In ferroptosis, mitochondria  
11 exhibit distinct morphological alterations, including outer membrane rupture and reduced  
12 or disorganized mitochondrial cristae.<sup>21</sup> Notably, our ultrastructural analysis of normal  
13 sebaceous glands revealed frequent mitochondria with cristae disorganization in  
14 terminally differentiated sebocytes, a morphology consistent with ferroptosis-associated  
15 changes, whereas patient tissues showed a remarkable decrease in mitochondria with  
16 cristae disorganization (Figure 2a, b). Given prior evidence that enhanced *NNT* activity  
17 confers ferroptosis resistance in gastric cancer,<sup>20</sup> we hypothesized that  
18 the *NNT* c.2063T>G variant also enhances resistance to ferroptosis in sebocytes, thereby  
19 reducing their susceptibility to ferroptosis. To test this, we assessed the expression of 4-  
20 HNE, a key lipid peroxidation marker, by immunofluorescence in lesional skin from two

1 patients (Fam1:III-2 and Fam2:II-2) and two healthy controls. A significant decrease in  
2 the levels of 4-HNE in patients (Figure 4a, b) was detected compared to controls,  
3 suggesting reduced ferroptosis susceptibility in sebaceous glands.

#### 4 5 ***NNT* c.2063T>G variant conferred ferroptosis resistance in SZ95 sebocytes**

6 To determine whether the *NNT* c.2063T>G variant confers ferroptosis resistance in  
7 sebocytes, we analyzed lipid peroxidation and cell death in *NNT*-knockdown SZ95  
8 sebocytes expressing EV, r*NNT*-WT, or r*NNT*-Leu688Trp. Cells were treated with the  
9 ferroptosis inducer RSL3, with or without the antioxidant N-acetylcysteine (NAC). Under  
10 basal conditions, all groups exhibited comparable lipid peroxidation levels and viability  
11 (Figure 5a-d). RSL3 exposure triggered pronounced lipid peroxidation and cell death in  
12 EV-transfected cells, while cells expressing r*NNT*-WT showed partial mitigation of these  
13 effects (Figure 5a-d), indicating that *NNT* can mitigate RSL3-induced ferroptosis in SZ95  
14 sebocytes. Remarkably, compared to the cells expressing r*NNT*-WT, cells expressing  
15 r*NNT*-Leu688Trp demonstrated substantially attenuated lipid peroxidation and superior  
16 survival (Figure 5a-d), indicating enhanced ferroptosis resistance conferred by the  
17 Leu688Trp variant.

18

19 Notably, NAC co-treatment abolished RSL3-induced lipid peroxidation and cell death  
20 in all groups (Figure 5a-d), confirming oxidative stress as the primary driver of



1 ferroptosis. Together with our findings that the variant significantly enhances NNT-  
2 mediated antioxidant capacity, these results suggest that the *NNT* c.2063T>G  
3 (p.Leu688Trp) variant markedly increases sebocytes resistance to ferroptosis through  
4 oxidative stress mitigation.

5

## 6 **Discussion**

7 In this study, we identified *NNT* as a causative gene for PDFSH. We demonstrate that a  
8 gain-of-function variant in *NNT* enhances resistance to ferroptosis in sebocytes,  
9 contributing to the pathogenesis of SGH. NNT serves as a pivotal mitochondrial enzyme,  
10 generating NADPH through proton gradient coupling.<sup>8,9</sup> This mitochondrial NADPH  
11 pool sustains GSH redox cycling, a critical defense mechanism against ROS that governs  
12 cellular survival.<sup>12</sup> Consistently, *nnt-1* deletion mutants in *Caenorhabditis*  
13 *elegans* exacerbate oxidative stress susceptibility via impaired GSH/GSSG ratio,<sup>22</sup> while  
14 NNT-knockdown in human PC12 cells disrupts redox homeostasis through NADPH  
15 depletion, GSH imbalance, and H<sub>2</sub>O<sub>2</sub> accumulation.<sup>23</sup> In FGD, biallelic loss-of-  
16 function variants in *NNT* cause oxidative dysregulation characterized by GSH depletion,  
17 ROS accumulation, and cell death,<sup>13,14,24</sup> underscoring essential roles of NNT in oxidative  
18 defense. In contrast, our patient-derived primary keratinocytes showed an increase of  
19 NADPH/NADP<sup>+</sup> ratio and GSH levels with concomitant ROS reduction compared to the

1 healthy control. Similarly, NNT-knockdown SZ95 sebocytes expressing the rNNT-  
2 Leu688Trp showed a higher NADPH/NADP<sup>+</sup> ratio, elevated GSH levels, and decreased  
3 ROS levels compared to cells expressing rNNT-WT. These data collectively demonstrate  
4 that the c.2063T>G variant enhances NNT catalytic efficiency to regulate redox  
5 homeostasis, thus exerting a gain-of-function property.

6  
7 NNT comprises three functional domains: the NAD(H)-binding domain (dI), the  
8 transmembrane proton channel domain (dII), and the NADP(H)-binding domain (dIII).  
9 Mutagenesis studies in *E. coli* have demonstrated that alanine or cysteine substitutions at  
10 conserved residues Ser250, Ser251, or Ser256 of *E. coli* (homologous to human NNT  
11 Ser867, Ser868, and Ser873) within transmembrane helix 14 (TM14) of the dII enhance  
12 NNT activity.<sup>25,26</sup> This functional enhancement may occur through induced  
13 conformational changes at the dIII-dII interface (facilitated by their spatial proximity) or  
14 through structural modulation of key transmembrane helices in the central dII.<sup>25-27</sup> These  
15 structural alterations may either optimize NADP(H)-binding dynamics via allosteric  
16 coupling to enhance catalytic efficiency or stabilize the open state of the proton channel  
17 in dII, thereby improving proton translocation efficiency.<sup>25-27</sup> Residue 688 is located  
18 within TM8 of dII, spatially proximal to the dIII-dII interface. The Leu688Trp  
19 substitution replaces the wild-type hydrophobic aliphatic residue leucine with a  
20 tryptophan residue that harbors a rigid indole ring. This substitution is likely to strengthen

1 aromatic interactions (residues Phe, Trp, and Tyr), particularly  $\pi$ - $\pi$  stacking, which are  
2 critical for protein folding, thermal stability, and conformational regulation of  
3 transmembrane proteins.<sup>28-30</sup> We hypothesize that the Leu688Trp substitution might  
4 optimize the dIII-dII interface or stabilize the open conformation of the proton channel to  
5 improve the coupling efficiency between NADPH production and proton translocation,  
6 leading to gain-of-function changes. A representative example of such a mechanism is  
7 *KCNC2*, which encodes the voltage-gated potassium ( $K^+$ ) channel subunit Kv3.2. The  
8 Cys125Tyr substitution, located near the  $\alpha$ -6 helix of the cytoplasmic tetramerization  
9 domain—a key regulator of channel gating—introduces a phenol side chain that forms  $\pi$ -  
10  $\pi$  stacking interactions with Tyr156.<sup>30</sup> This interaction stabilizes the open conformation of  
11 the channel, leading to a significant hyperpolarizing shift in voltage-dependent activation,  
12 which represents a distinct gain-of-function phenotype.<sup>30</sup> Further functional studies are  
13 warranted to demonstrate the conformational changes and functional alterations of NNT  
14 by Leu688Trp substitution.

15  
16 NNT critically promotes tumor progression by maintaining redox homeostasis and Fe-  
17 S protein function.<sup>10,15,20</sup> In gastric cancer, Han *et al.* demonstrated that enhanced NNT  
18 activity protects tumor cells from ferroptosis through Fe-S cluster stabilization,  
19 highlighting NNT as a key ferroptosis modulator.<sup>20</sup> Ferroptosis is regulated by oxidative  
20 stress and antioxidant capacity, in which ROS-driven lipid peroxidation generates

1 cytotoxic products such as 4-HNE.<sup>11,21,31</sup> Our TEM analysis revealed reduced ferroptosis-  
2 associated mitochondrial ultrastructures in terminally differentiated sebocytes in the  
3 patient with PDFSH. Consistently, the patients' skin lesion exhibited reduced 4-HNE  
4 levels, together suggesting decreased susceptibility to ferroptosis. NNT-knockdown SZ95  
5 sebocytes expressing rNNT-Leu688Trp showed enhanced antioxidant capacity and  
6 resistance to RSL3-induced ferroptosis. Co-treatment with NAC completely reversed  
7 RSL3-induced ferroptosis. These results implicate that the *NNT* c.2063T>G variant  
8 confers sebocytes resistance to ferroptosis through oxidative stress mitigation. A recent  
9 study has revealed that near-infrared radiation (NIR), which induces intracellular ROS  
10 elevation,<sup>32</sup> triggers ferroptosis in sebocytes<sup>18</sup>—suggesting ferroptosis mediates stress-  
11 induced sebocyte death. Thus, we hypothesize that *NNT* c.2063T>G variant primarily  
12 confers protection against sebocyte ferroptosis under stressful conditions (e.g., solar  
13 exposure including UV, visible light, and NIR). This protection likely elevates the  
14 ferroptosis resistance threshold, postponing the death of mature sebocytes and leading to  
15 slow progressive accumulation of mature sebocytes in the sebaceous gland. This  
16 phenomenon of postponed cell death causing sebocyte accumulation parallels the  
17 findings of Atsugi *et al.*, where tight junction barrier defects impaired mature sebocyte  
18 degradation during holocrine secretion, leading to accumulated incompletely degenerated  
19 sebocytes in sebaceous ducts.<sup>33</sup>

20

1 Notably, cutaneous biology studies have demonstrated that sebaceous glands inherently  
2 sustain elevated NADPH concentrations relative to adjacent epidermal compartments.<sup>34,35</sup>  
3 This is further demonstrated by our immunohistochemical analysis showing pronounced  
4 NNT immunoreactivity in sebaceous units compared to interfollicular epidermis (Figure  
5 S3c). It's tempting to assume that NADPH-dependent redox maintenance exerts greater  
6 functional significance in sebaceous glands than interfollicular epidermis, which is  
7 further supported by the fact that the gain-of-function variant in *NNT* causes sebaceous  
8 gland-specific phenotype of PDFSH, rather than epidermal differentiation disorders.

9  
10 In summary, we identify a gain-of-function *NNT* variant as a cause of PDFSH through  
11 enhanced ferroptosis resistance of sebocytes. Our study not only expands the *NNT*-  
12 associated disease spectrum, but also paves a new avenue for developing future  
13 therapeutic interventions for SGH.

## 14 15 **References**

- 16 1. Hou X, Wei Z, Zouboulis CC, *et al.* Aging in the sebaceous gland. *Frontiers in Cell and*  
17 *Developmental Biology.* 2022;10.
- 18 2. Boschnakow A, May T, Assaf C, *et al.* Ciclosporin A-induced sebaceous gland  
19 hyperplasia. *Br J Dermatol.* 2003;149:198-200.
- 20 3. Engel F, Ellero B, Woehl-Jaegle ML, *et al.* Hyperplasies sébacées profuses du visage  
21 induites par la ciclosporine. *Annales de Dermatologie et de Vénéréologie.* 2005;132:342-  
22 345.

- 1 4. Marcusson JA, Bjarnason B, Ros AM. Isotretinoin for sebaceous skin lesions in Muir-Torre syndrome: a case report. *Acta Derm Venereol.* 1998;78:479-480.
- 2
- 3 5. Boonchai W, Leenutaphong V. Familial presenile sebaceous gland hyperplasia. *J Am Acad Dermatol.* 1997;36:120-122.
- 4
- 5 6. Liu YCS, Cheng YP, Liu CI, *et al.* Presenile diffuse familial sebaceous hyperplasia successfully treated with low-dose isotretinoin: A report of two cases and review of the published work. *The Journal of Dermatology.* 2016;43:1205-1208.
- 6
- 7
- 8 7. Piletta PA, Calza AM, Masouyé I, *et al.* Hypohidrotic ectodermal dysplasia with recurrent otitis and sebaceous gland hypertrophy of the face. *Dermatology.* 1995;191:355-358.
- 9
- 10
- 11 8. Hoek JB, Rydström J. Physiological roles of nicotinamide nucleotide transhydrogenase. *Biochem J.* 1988;254:1-10.
- 12
- 13 9. Kampjut D, Sazanov LA. Structure and mechanism of mitochondrial proton-translocating transhydrogenase. *Nature.* 2019;573:291-295.
- 14
- 15 10. Ward NP, Kang YP, Falzone A, *et al.* Nicotinamide nucleotide transhydrogenase regulates mitochondrial metabolism in NSCLC through maintenance of Fe-S protein function. *J Exp Med.* 2020;217.
- 16
- 17
- 18 11. Tang D, Chen X, Kang R, *et al.* Ferroptosis: molecular mechanisms and health implications. *Cell Research.* 2020;31:107-125.
- 19
- 20 12. Circu ML, Aw TY. Reactive oxygen species, cellular redox systems, and apoptosis. *Free Radical Biology and Medicine.* 2010;48:749-762.
- 21
- 22 13. Meimaridou E, Kowalczyk J, Guasti L, *et al.* Mutations in NNT encoding nicotinamide nucleotide transhydrogenase cause familial glucocorticoid deficiency. *Nature Genetics.* 2012;44:740-742.
- 23
- 24
- 25 14. Bodoni AF, Coeli-Lacchini FB, Gebenlian JL, *et al.* Nicotinamide Nucleotide Transhydrogenase Is Essential for Adrenal Steroidogenesis: Clinical and In Vitro Lessons. *The Journal of Clinical Endocrinology & Metabolism.* 2023;108:1464-1474.
- 26
- 27
- 28 15. Li S, Zhuang Z, Wu T, *et al.* Nicotinamide nucleotide transhydrogenase-mediated redox homeostasis promotes tumor growth and metastasis in gastric cancer. *Redox Biology.* 2018;18:246-255.
- 29
- 30
- 31 16. Chen X, Kang R, Kroemer G, *et al.* Organelle-specific regulation of ferroptosis. *Cell Death Differ.* 2021;28:2843-2856.
- 32
- 33 17. Dixon SJ, Olzmann JA. The cell biology of ferroptosis. *Nat Rev Mol Cell Biol.* 2024;25:424-442.
- 34
- 35 18. Wu R, Li J, Tian H, *et al.* Unveiling the mechanism of photothermal therapy in acne management: targeting sebaceous gland ferroptosis via umbilical cord mesenchymal stem cell membrane-encapsulated Au-Ag-PDA. *Front Bioeng Biotechnol.* 2024;12:1426477.
- 36
- 37
- 38 19. Zouboulis CC, Seltmann H, Neitzel H, *et al.* Establishment and characterization of an immortalized human sebaceous gland cell line (SZ95). *J Invest Dermatol.* 1999;113:1011-39

- 1 1020.
- 2 20. Han Y, Zhang Y-Y, Pan Y-Q, *et al.* IL-1 $\beta$ -associated NNT acetylation orchestrates iron-  
3 sulfur cluster maintenance and cancer immunotherapy resistance. *Molecular Cell.*  
4 2023;83:1887-1902.e1888.
- 5 21. Liu Ye, Lu S, Wu L-l, *et al.* The diversified role of mitochondria in ferroptosis in cancer.  
6 *Cell Death & Disease.* 2023;14.
- 7 22. Arkblad EL, Tuck S, Pestov NB, *et al.* A *Caenorhabditis elegans* mutant lacking  
8 functional nicotinamide nucleotide transhydrogenase displays increased sensitivity to  
9 oxidative stress. *Free Radical Biology and Medicine.* 2005;38:1518-1525.
- 10 23. Yin F, Sancheti H, Cadenas E. Silencing of nicotinamide nucleotide transhydrogenase  
11 impairs cellular redox homeostasis and energy metabolism in PC12 cells. *Biochimica et*  
12 *Biophysica Acta (BBA) - Bioenergetics.* 2012;1817:401-409.
- 13 24. Weinberg-Shukron A, Abu-Libdeh A, Zhadeh F, *et al.* Combined mineralocorticoid and  
14 glucocorticoid deficiency is caused by a novel founder nicotinamide nucleotide  
15 transhydrogenase mutation that alters mitochondrial morphology and increases oxidative  
16 stress. *Journal of Medical Genetics.* 2015;52:636-641.
- 17 25. Yamaguchi M, Stout CD, Hatefi Y. The proton channel of the energy-transducing  
18 nicotinamide nucleotide transhydrogenase of *Escherichia coli*. *J Biol Chem.*  
19 2002;277:33670-33675.
- 20 26. Karlsson J, Althage M, Rydström J. Roles of individual amino acids in helix 14 of the  
21 membrane domain of proton-translocating transhydrogenase from *Escherichia coli* as  
22 deduced from cysteine mutagenesis. *Biochemistry.* 2003;42:6575-6581.
- 23 27. Yamaguchi M, Stout CD. Essential glycine in the proton channel of *Escherichia coli*  
24 transhydrogenase. *J Biol Chem.* 2003;278:45333-45339.
- 25 28. Meyer EA, Castellano RK, Diederich F. Interactions with aromatic rings in chemical  
26 and biological recognition. *Angew Chem Int Ed Engl.* 2003;42:1210-1250.
- 27 29. Duan J, Li Z, Li J, *et al.* Structure of full-length human TRPM4. *Proc Natl Acad Sci U*  
28 *S A.* 2018;115:2377-2382.
- 29 30. Clatot J, Currin CB, Liang Q, *et al.* A structurally precise mechanism links an epilepsy-  
30 associated KCNC2 potassium channel mutation to interneuron dysfunction. *Proc Natl*  
31 *Acad Sci U S A.* 2024;121:e2307776121.
- 32 31. Wang B, Wang Y, Zhang J, *et al.* ROS-induced lipid peroxidation modulates cell death  
33 outcome: mechanisms behind apoptosis, autophagy, and ferroptosis. *Arch Toxicol.*  
34 2023;97:1439-1451.
- 35 32. Barolet D, Christiaens F, Hamblin MR. Infrared and skin: Friend or foe. *J Photochem*  
36 *Photobiol B.* 2016;155:78-85.
- 37 33. Atsugi T, Yokouchi M, Hirano T, *et al.* Holocrine Secretion Occurs outside the  
38 Tight Junction Barrier in Multicellular Glands: Lessons from Claudin-1-Deficient Mice. *J*  
39 *Invest Dermatol.* 2020;140:298-308.e295.

- 1 34. Im MJ, Hoopes JE. Enzymes of carbohydrate metabolism in normal human sebaceous  
2 glands. *J Invest Dermatol.* 1974;62:153-160.  
3 35. Im MJ, Hoopes JE. Quantitative histochemistry of nicotinamide adenine nucleotides in  
4 human skin. *J Invest Dermatol.* 1970;55:277-281.

5

## 6 **Figure Legend**

### 7 **Figure 1. Clinical, histopathologic features and pedigrees of three families with** 8 **PDFSH.**

9 (a-b) Multiple pale yellow to flesh-colored papules on the face, sparing periocular and  
10 perioral regions. Some lesions show central umbilication and mild erythema at the base in  
11 Fam2:II-2 (a) and Fam1:III-2 (b).

12 (c) Histopathology of Fam1:III-2 shows increased hypertrophic sebaceous glands  
13 localized in the superficial dermis, containing abundant mature sebocytes, with  
14 infiltration of inflammatory cells in the superficial dermis. Scale bar = 250µm.

15 (d) Pedigrees of the autosomal-dominant PDFSH were analyzed in the study. Filled  
16 symbols indicate affected individuals with PDFSH. Arrows denote probands. Black stars  
17 denote individuals whose DNA samples were obtained.

18

### 19 **Figure 2. Ultrastructural features and Sanger sequencing.**

20 (a) Transmission electron microscopy (TEM) of terminally differentiated sebaceous  
21 glands between healthy control and Fam2:II-2. Yellow stars denote mitochondria with  
22 cristae disorganization. Scale bars = 5µm.

23 (b) Quantitative analysis revealed a marked decrease in the proportion of mitochondria  
24 with cristae disorganization in the patient Fam2:II-2 compared to the healthy control.

25 Error bars represent SEM; two-tailed Student's t-test; \*\*p<0.01.

26 (c) Sanger sequencing showed the *NNT* c.2063T>G variant in the affected individuals.

27 (d) Sequence alignment showed that the affected residue Leu688 in *NNT* is highly  
28 conserved across species.



1

2 **Figure 3. Redox imbalance in patient-derived keratinocytes and NNT-knockdown**  
3 **SZ95 sebocytes.**

4 (a-c) Primary keratinocytes from patient Fam2:II-2 and healthy control were measured,  
5 including (a) NADPH/NADP<sup>+</sup> ratio, (b) glutathione (GSH) levels, and (c) relative  
6 reactive oxygen species (ROS) levels. n = 3 replicates. Error bars represent SEM; two-  
7 tailed Student's t-test; \*p<0.05, \*\*p<0.01.

8 (d-f) (d) NADPH/NADP<sup>+</sup> ratio, (e) GSH levels, and (f) relative ROS levels were  
9 analyzed in NNT-knockdown SZ95 sebocytes expressing either empty vector (EV), short  
10 hairpin RNA (shRNA)-resistant (r) wild-type NNT (rNNT-WT), or the NNT-Leu688Trp  
11 variant (rNNT-Leu688Trp). n = 3 replicates. Error bars represent SEM; one-way  
12 ANOVA; \*p<0.05, \*\*p<0.01.

13

14 **Figure 4. Lipid peroxidation in sebaceous glands.**

15 (a-b) Immunofluorescence staining of the lipid peroxidation marker 4-HNE showed  
16 reduced levels in sebaceous glands of the skin sections from Fam1:III-2 (a) and Fam2:II-  
17 2 (b) in comparison to two healthy controls. Scale bars = 100µm.

18

19 **Figure 5. The NNT c.2063T>G variant mitigates ferroptosis in SZ95 sebocytes.**

20 (a-b) Lipid peroxidation analysis in NNT-knockdown SZ95 sebocytes expressing EV,  
21 rNNT-WT, or rNNT-Leu688Trp, followed by treatment with 0.4µM RSL3 for 6 h.

22 Representative images (a) and quantification data are shown (b). n = 3 replicates. Error  
23 bars represent SEM; one-way ANOVA; \*\*p<0.01; ns, not significant.

24 (c-d) Images (c) and flow cytometry quantification (d) of PI staining in NNT-knockdown  
25 SZ95 sebocytes expressing EV, rNNT-WT, or rNNT-Leu688Trp, followed by treatment  
26 with 0.5µM RSL3 for 6 h. n = 3 replicates. Error bars represent SEM; one-way ANOVA;

1 \*\*p<0.01; ns, not significant.

2

3



4

5


6

Figure 1a  
119x179 mm (DPI)




1  
2  
3  
4

Figure 1b  
147x79 mm (DPI)



5  
6  
7

Figure 1c  
147x96 mm (DPI)



1  
2  
3  
4

Figure 1d  
147x143 mm (DPI)




Figure 2a  
117x97 mm (DPI)

1  
2  
3  
4

ACCEPTED MANUSCRIPT




Figure 2b

56x97 mm (DPI)

1  
2  
3  
4




Figure 2c  
75x62 mm (DPI)






Figure 2d  
114x62 mm (DPI)

1  
2  
3  
4  
5  
6  
7  
8



1  
2  
3  
4


Figure 3a  
51x60 mm (DPI)



5  
6  
7  
8

Figure 3b  
53x60 mm (DPI)






1

2

3

4

Figure 3c  
50x60 mm (DPI)



5

6

7

8

Figure 3d  
51x74 mm (DPI)




Figure 3e  
53x74 mm (DPI)




Figure 3f  
50x74 mm (DPI)

1

2

3

4

5

6

7

8




Figure 4a  
94x94 mm (DPI)

1  
2  
3  
4




Figure 4b  
94x94 mm (DPI)




Figure 5a  
93x53 mm (DPI)

1  
2  
3  
4  
5  
6  
7  
8




Figure 5b  
85x64 mm (DPI)




Figure 5c  
82x82 mm (DPI)

1

2

3


4

5

6

7

8



1

2

3

Figure 5d  
85x66 mm (DPI)